Aptose Biosciences Files 8-K
Ticker: APTOF · Form: 8-K · Filed: Nov 20, 2024 · CIK: 882361
Sentiment: neutral
Topics: filing, financials, disclosure
Related Tickers: APTO
TL;DR
APTO filed an 8-K on Nov 20, 2024, covering Reg FD and financials. Check it out.
AI Summary
Aptose Biosciences Inc. filed an 8-K on November 20, 2024, reporting on Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as Lorus Therapeutics Inc. and Imutec Pharma Inc., is based in Toronto, Canada, and operates in the biological products sector.
Why It Matters
This filing provides updates on Aptose Biosciences' regulatory disclosures and financial statements, which are crucial for investors to assess the company's current standing and future prospects.
Risk Assessment
Risk Level: low — This is a routine filing of an 8-K, providing standard disclosures and financial information without any immediate, significant events.
Key Players & Entities
- Aptose Biosciences Inc. (company) — Registrant
- November 20, 2024 (date) — Date of earliest event reported
- Lorus Therapeutics Inc. (company) — Former company name
- Imutec Pharma Inc. (company) — Former company name
- Toronto, Canada (location) — Company headquarters
FAQ
What is the primary purpose of this 8-K filing for Aptose Biosciences Inc.?
The primary purpose of this 8-K filing is to report on Regulation FD Disclosure and Financial Statements and Exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on November 20, 2024.
What were Aptose Biosciences Inc.'s former company names?
Aptose Biosciences Inc. was formerly known as Lorus Therapeutics Inc. and Imutec Pharma Inc.
In which industry sector does Aptose Biosciences Inc. operate?
Aptose Biosciences Inc. operates in the Biological Products (No Diagnostic Substances) sector.
Where is Aptose Biosciences Inc. headquartered?
Aptose Biosciences Inc. is headquartered in Toronto, Canada.
Filing Stats: 507 words · 2 min read · ~2 pages · Grade level 9.7 · Accepted 2024-11-20 08:00:24
Filing Documents
- f8k_112024.htm (8-K) — 15KB
- exh_991.htm (EX-99.1) — 8KB
- 0001171843-24-006474.txt ( ) — 223KB
- gnw-20190101.xsd (EX-101.SCH) — 3KB
- gnw-20190101_def.xml (EX-101.DEF) — 25KB
- gnw-20190101_lab.xml (EX-101.LAB) — 33KB
- gnw-20190101_pre.xml (EX-101.PRE) — 22KB
- f8k_112024_htm.xml (XML) — 3KB
01. Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure. On November 20, 2024, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference. In accordance with General Instruction B.2 of Form 8-K, the information in the press release attached as Exhibit 99.1 hereto shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Press Release dated November 20, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Aptose Biosciences Inc. Date: November 20, 2024 By: /s/ William G. Rice, Ph.D. William G. Rice, Ph.D. Chairman, President, and Chief Executive Officer